Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FKBP1A | P62942 | 1/20 | 0.61 |
| ▸ | ENPP2 | Q13822 | 6/20 | 0.52 |
| ▸ | MAPT | P10636 | 4/20 | 0.48 |
| ▸ | POLB | P06746 | 3/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | ATXN2 | Q99700 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6411459 | 0.81 | FKBP1A (0.58) | FKBP1AENPP2MAPTPOLBMEN1 | |
| SCHEMBL6411463 | 0.79 | FKBP1A (0.56) | FKBP1AENPP2MAPTPOLBMEN1 | |
| SCHEMBL15309104 | 0.78 | PKM (0.52) | — | |
| SCHEMBL15309154 | 0.75 | RAB9A (0.58) | MAPTPOLBMEN1KMT2ARAB9A | |
| SCHEMBL15134821 | 0.74 | GAA (0.74) | FKBP1AENPP2MAPTPOLBMEN1 | |
| SCHEMBL656547 | 0.74 | FKBP1A (0.72) | FKBP1AENPP2MAPTPOLBMEN1 | |
| SCHEMBL2402439 | 0.74 | ALDH1A1 (0.52) | FKBP1AENPP2MAPTPOLBMEN1 | |
| SCHEMBL15309125 | 0.73 | GRM5 (0.54) | — | |
| SCHEMBL6410978 | 0.73 | FKBP1A (0.48) | FKBP1AENPP2MAPTPOLBMEN1 | |
| SCHEMBL2399304 | 0.72 | FKBP1A (0.48) | FKBP1AENPP2MAPTPOLBMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8048890-B2 | Analgesics; neuropathic pain; headaches; muscle relaxants; incontence; tinnitus; diarrhea; antiarrhythmia agents; antiischemic agents; antiinflammatory agents; antiulcer agents; antidepressants; antiepileptic agents | GRUENENTHAL GMBH (DE) | 2011-11-01 | — | — | US | disclosed |
| US-20110224172-A1 | Substituted 1-Oxa-2,8-Diaza-Spiro [4,5] Dec-2-Ene Derivatives and Related Treatment Methods | GRUENENTHAL GMBH (DE) | 2011-09-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110224172-A1 | Substituted 1-Oxa-2,8-Diaza-Spiro [4,5] Dec-2-Ene Derivatives and Related Treatment Methods | SULT1E1, DECR1, CYP8B1 | FKBP1A 3177/4885ENPP2 3412/4885MAPT 3594/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.